476 results
Search Results
2. Oral phytate supplementation on the progression of mild cognitive impairment, brain iron deposition and diabetic retinopathy in patients with type 2 diabetes: a concept paper for a randomized double blind placebo controlled trial (the PHYND trial).
- Author
-
Pujol A, Sanchis P, Tamayo MI, Nicolau J, Grases F, Espino A, Estremera A, Rigo E, Amengual GJ, Rodríguez M, Ribes JL, Gomila I, Simó-Servat O, and Masmiquel L
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Administration, Oral, Double-Blind Method, Randomized Controlled Trials as Topic, Brain metabolism, Brain drug effects, Cognitive Dysfunction metabolism, Cognitive Dysfunction etiology, Cognitive Dysfunction prevention & control, Diabetes Mellitus, Type 2 metabolism, Diabetes Mellitus, Type 2 complications, Diabetic Retinopathy metabolism, Diabetic Retinopathy drug therapy, Dietary Supplements, Disease Progression, Iron metabolism, Iron administration & dosage, Phytic Acid administration & dosage
- Abstract
Type 2 diabetes mellitus has a worldwide prevalence of 10.5% in the adult population (20-79 years), and by 2045, the prevalence is expected to keep rising to one in eight adults living with diabetes. Mild cognitive impairment has a global prevalence of 19.7% in adults aged 50 years. Both conditions have shown a concerning increase in prevalence rates over the past 10 years, highlighting a growing public health challenge. Future forecasts indicate that the prevalence of dementia (no estimations done for individuals with mild cognitive impairment) is expected to nearly triple by 2050. Type 2 diabetes mellitus is a risk factor for the development of cognitive impairment, and such impairment increase the likelihood of poor glycemic/metabolic control. High phytate intake has been shown to be a protective factor against the development of cognitive impairment in observational studies. Diary phytate intake might reduce the micro- and macrovascular complications of patients with type 2 diabetes mellitus through different mechanisms. We describe the protocol of the first trial (the PHYND trial) that evaluate the effect of daily phytate supplementation over 56 weeks with a two-arm double-blind placebo-controlled study on the progression of mild cognitive impairment, cerebral iron deposition, and retinal involvement in patients with type 2 diabetes mellitus. Our hypothesis proposes that phytate, by inhibiting advanced glycation end product formation and chelating transition metals, will improve cognitive function and attenuate the progression from Mild Cognitive Impairment to dementia in individuals with type 2 diabetes mellitus and mild cognitive impairment. Additionally, we predict that phytate will reduce iron accumulation in the central nervous system, mitigate neurodegenerative changes in both the central nervous system and retina, and induce alterations in biochemical markers associated with neurodegeneration., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Pujol, Sanchis, Tamayo, Nicolau, Grases, Espino, Estremera, Rigo, Amengual, Rodríguez, Ribes, Gomila, Simó-Servat and Masmiquel.)
- Published
- 2024
- Full Text
- View/download PDF
3. Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper.
- Author
-
Perucca, Emilio, French, Jacqueline A., Aljandeel, Ghaieb, Balestrini, Simona, Braga, Patricia, Burneo, Jorge G., Felli, Augustina Charway, Cross, J. Helen, Galanopoulou, Aristea S., Jain, Satish, Jiang, Yuwu, Kälviäinen, Reetta, Lim, Shih Hui, Meador, Kimford J., Mogal, Zarine, Nabbout, Rima, Sofia, Francesca, Somerville, Ernest, Sperling, Michael R., and Triki, Chahnez
- Subjects
- *
SEIZURES (Medicine) , *DRUGS , *DIRECT action , *MEDICAL care , *DISEASE progression - Abstract
A variety of terms, such as "antiepileptic," "anticonvulsant," and "antiseizure" have been historically applied to medications for the treatment of seizure disorders. Terminology is important because using terms that do not accurately reflect the action of specific treatments may result in a misunderstanding of their effects and inappropriate use. The present International League Against Epilepsy (ILAE) position paper used a Delphi approach to develop recommendations on English‐language terminology applicable to pharmacological agents currently approved for treating seizure disorders. There was consensus that these medications should be collectively named "antiseizure medications". This term accurately reflects their primarily symptomatic effect against seizures and reduces the possibility of health care practitioners, patients, or caregivers having undue expectations or an incorrect understanding of the real action of these medications. The term "antiseizure" to describe these agents does not exclude the possibility of beneficial effects on the course of the disease and comorbidities that result from the downstream effects of seizures, whenever these beneficial effects can be explained solely by the suppression of seizure activity. It is acknowledged that other treatments, mostly under development, can exert direct favorable actions on the underlying disease or its progression, by having "antiepileptogenic" or "disease‐modifying" effects. A more‐refined terminology to describe precisely these actions needs to be developed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Critically appraised paper: In adolescents with moderate-grade idiopathic scoliosis, nighttime bracing with self-mediated physical activity prevented Cobb angle progression [synopsis].
- Author
-
Milne, Nikki
- Subjects
HOSPITAL night care ,SCOLIOSIS ,EXERCISE therapy ,ORTHOPEDIC apparatus ,DISEASE progression ,PHYSICAL activity ,ADOLESCENCE - Abstract
The article explores how nighttime bracing combined with self-mediated physical activity can effectively prevent the progression of the Cobb angle in adolescents with moderate-grade idiopathic scoliosis. Topics discussed include the mechanisms of nighttime bracing in scoliosis management, the role of self-directed physical activities in supporting spinal health, and the overall outcomes in slowing disease progression with this combined approach.
- Published
- 2024
- Full Text
- View/download PDF
5. The incidence and prevalence of diabetic macular edema and proliferative diabetic retinopathy, their progression to visual impairment and patterns in their intravitreal treatment in the Finnish population.
- Author
-
Heloterä H, Arffman M, Sund R, Keskimäki I, and Kaarniranta K
- Subjects
- Humans, Incidence, Finland epidemiology, Male, Female, Prevalence, Middle Aged, Aged, Adult, Registries, Young Adult, Retrospective Studies, Follow-Up Studies, Vascular Endothelial Growth Factor A antagonists & inhibitors, Diabetic Retinopathy epidemiology, Diabetic Retinopathy drug therapy, Diabetic Retinopathy complications, Diabetic Retinopathy diagnosis, Macular Edema epidemiology, Macular Edema drug therapy, Macular Edema etiology, Intravitreal Injections, Angiogenesis Inhibitors administration & dosage, Visual Acuity, Disease Progression
- Abstract
Purpose: The worldwide prevalence of diabetes mellitus (DM) continues to increase. As DM is linked to various ophthalmological comorbidities, it is crucial to understand the incidence and the treatment patterns of these complications to minimise the treatment burden for the patient and the healthcare system. This study aims to evaluate the incidence and prevalence of diabetic macular oedema (DME) and proliferative diabetic retinopathy (PDR) and to analyse intravitreal (IVT) treatment patterns and responses in the Finnish population with diabetes., Methods: A nationwide data register containing details of over 20-year-old individuals with diabetes was used in the analyses., Results: The incidence and prevalence of DME and PDR among the Finnish population with diabetes either declined or remained stable during 2007-2017 (Incidence rate: DME -40.8%, PDR -65.3%; prevalence rate: DME +4.7%, PDR -11.2%). During the same period, number of persons suffering from diabetes increased by +58.3%. The total number of IVT injections increased by 261.7%; the number of patients receiving IVT treatments increased by 133.6% from 2011 to 2017, reflecting changes in patient numbers in the ophthalmology departments. Furthermore, irrespective of the rising number of patients with diabetes, the numbers with visual impairment declined by 75.8% among DME and by 75.7% among PDR patients in 2007-2017., Conclusions: Regardless of the considerable increase in the workload of ophthalmology departments, the healthcare system has been able to reduce both the age and sex standardised incidence of DME and PDR among the diabetic population suffering from a visual impairment associated with this disease., (© 2024 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.)
- Published
- 2024
- Full Text
- View/download PDF
6. Nature of the evidence base and approaches to guide nutrition interventions for individuals: a position paper from the Academy of Nutrition Sciences.
- Author
-
Hickson, Mary, Papoutsakis, Constantina, Madden, Angela M, Smith, Mary Anne, and Whelan, Kevin
- Subjects
DIETETICS ,MEDICAL protocols ,PROFESSIONAL practice ,NATURAL foods ,PROFESSIONAL associations ,FOOD security ,NUTRITIONAL requirements ,MISINFORMATION ,INFORMATION resources ,NON-communicable diseases ,DIETETICS research ,NUTRITION services ,EVIDENCE-based medicine ,DIET ,DISEASE progression ,NUTRITION education - Abstract
This Position Paper from the Academy of Nutrition Sciences is the third in a series which describe the nature of the scientific evidence and frameworks that underpin nutrition recommendations for health. This paper focuses on evidence which guides the application of dietary recommendations for individuals. In some situations, modified nutrient intake becomes essential to prevent deficiency, optimise development and health, or manage symptoms and disease progression. Disease and its treatment can also affect taste, appetite and ability to access and prepare foods, with associated financial impacts. Therefore, the practice of nutrition and dietetics must integrate and apply the sciences of food, nutrition, biology, physiology, behaviour, management, communication and society to achieve and maintain human health. Thus, there is huge complexity in delivering evidence-based nutrition interventions to individuals. This paper examines available frameworks for appraising the quality and certainty of nutrition research evidence, the development nutrition practice guidelines to support evidence implementation in practice and the influence of other sources of nutrition information and misinformation. The paper also considers major challenges in applying research evidence to an individual and suggests consensus recommendations to begin to address these challenges in the future. Our recommendations target three groups; those who deliver nutrition interventions to individuals, those funding, commissioning or undertaking research aimed at delivering evidence-based nutrition practice, and those disseminating nutritional information to individuals. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Tracking amyotrophic lateral sclerosis disease progression using passively collected smartphone sensor data.
- Author
-
Karas M, Olsen J, Straczkiewicz M, Johnson SA, Burke KM, Iwasaki S, Lahav A, Scheier ZA, Clark AP, Iyer AS, Huang E, Berry JD, and Onnela JP
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Mobile Applications, Walking physiology, Exercise physiology, Amyotrophic Lateral Sclerosis physiopathology, Amyotrophic Lateral Sclerosis diagnosis, Smartphone, Disease Progression, Accelerometry instrumentation
- Abstract
Background: Passively collected smartphone sensor data provide an opportunity to study physical activity and mobility unobtrusively over long periods of time and may enable disease monitoring in people with amyotrophic lateral sclerosis (PALS)., Methods: We enrolled 63 PALS who used Beiwe mobile application that collected their smartphone accelerometer and GPS data and administered the self-entry ALS Functional Rating Scale-Revised (ALSFRS-RSE) survey. We identified individual steps from accelerometer data and used the Activity Index to summarize activity at the minute level. Walking, Activity Index, and GPS outcomes were then aggregated into day-level measures. We used linear mixed effect models (LMMs) to estimate baseline and monthly change for ALSFRS-RSE scores (total score, subscores Q1-3, Q4-6, Q7-9, Q10-12) and smartphone sensor data measures, as well as the associations between them., Findings: The analytic sample (N = 45) was 64.4% male with a mean age of 60.1 years. The mean observation period was 292.3 days. The ALSFRS-RSE total score baseline mean was 35.8 and had a monthly rate of decline of -0.48 (p-value <0.001). We observed statistically significant change over time and association with ALSFRS-RSE total score for four smartphone sensor data-derived measures: walking cadence from top 1 min and log-transformed step count, step count from top 1 min, and Activity Index from top 1 min., Interpretation: Smartphone sensors can unobtrusively track physical changes in PALS, potentially aiding disease monitoring and future research., (© 2024 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.)
- Published
- 2024
- Full Text
- View/download PDF
8. mTOR and neuroinflammation in epilepsy: implications for disease progression and treatment.
- Author
-
Ravizza T, Scheper M, Di Sapia R, Gorter J, Aronica E, and Vezzani A
- Subjects
- Humans, Animals, Signal Transduction physiology, Brain metabolism, Brain pathology, Anticonvulsants therapeutic use, Anticonvulsants pharmacology, Epilepsy drug therapy, TOR Serine-Threonine Kinases metabolism, Neuroinflammatory Diseases drug therapy, Neuroinflammatory Diseases metabolism, Disease Progression
- Abstract
Epilepsy remains a major health concern as anti-seizure medications frequently fail, and there is currently no treatment to stop or prevent epileptogenesis, the process underlying the onset and progression of epilepsy. The identification of the pathological processes underlying epileptogenesis is instrumental to the development of drugs that may prevent the generation of seizures or control pharmaco-resistant seizures, which affect about 30% of patients. mTOR signalling and neuroinflammation have been recognized as critical pathways that are activated in brain cells in epilepsy. They represent a potential node of biological convergence in structural epilepsies with either a genetic or an acquired aetiology. Interventional studies in animal models and clinical studies give strong support to the involvement of each pathway in epilepsy. In this Review, we focus on available knowledge about the pathophysiological features of mTOR signalling and the neuroinflammatory brain response, and their interactions, in epilepsy. We discuss mitigation strategies for each pathway that display therapeutic effects in experimental and clinical epilepsy. A deeper understanding of these interconnected molecular cascades could enhance our strategies for managing epilepsy. This could pave the way for new treatments to fill the gaps in the development of preventative or disease-modifying drugs, thus overcoming the limitations of current symptomatic medications., (© 2024. Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF
9. The different risk of new-onset, chronic, worsening, and advanced heart failure: A systematic review and meta-regression analysis.
- Author
-
Shakoor A, Abou Kamar S, Malgie J, Kardys I, Schaap J, de Boer RA, van Mieghem NM, van der Boon RMA, and Brugts JJ
- Subjects
- Humans, Prognosis, Hospitalization statistics & numerical data, Chronic Disease, Risk Assessment methods, Cause of Death trends, Risk Factors, Global Health, Heart Failure epidemiology, Disease Progression
- Abstract
Aims: Heart failure (HF) is a chronic and progressive syndrome associated with a poor prognosis. While it may seem intuitive that the risk of adverse outcomes varies across the different stages of HF, an overview of these risks is lacking. This study aims to determine the risk of all-cause mortality and HF hospitalizations associated with new-onset HF, chronic HF (CHF), worsening HF (WHF), and advanced HF., Methods and Results: We performed a systematic review of observational studies from 2012 to 2022 using five different databases. The primary outcomes were 30-day and 1-year all-cause mortality, as well as 1-year HF hospitalization. Studies were pooled using random effects meta-analysis, and mixed-effects meta-regression was used to compare the different HF groups. Among the 15 759 studies screened, 66 were included representing 862 046 HF patients. Pooled 30-day mortality rates did not reveal a significant distinction between hospital-admitted patients, with rates of 10.13% for new-onset HF and 8.11% for WHF (p = 0.10). However, the 1-year mortality risk differed and increased stepwise from CHF to advanced HF, with a rate of 8.47% (95% confidence interval [CI] 7.24-9.89) for CHF, 21.15% (95% CI 17.78-24.95) for new-onset HF, 26.84% (95% CI 23.74-30.19) for WHF, and 29.74% (95% CI 24.15-36.10) for advanced HF. Readmission rates for HF at 1 year followed a similar trend., Conclusions: Our meta-analysis of observational studies confirms the different risk for adverse outcomes across the distinct HF stages. Moreover, it emphasizes the negative prognostic value of WHF as the first progressive stage from CHF towards advanced HF., (© 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
10. A scoping review of mathematical models covering Alzheimer's disease progression.
- Author
-
Moravveji, Seyedadel, Doyon, Nicolas, Mashreghi, Javad, and Duchesne, Simon
- Subjects
ALZHEIMER'S disease ,MATHEMATICAL models ,DISEASE progression ,TAU proteins ,PARTIAL differential equations - Abstract
Alzheimer's disease is a complex, multi-factorial, and multi-parametric neurodegenerative etiology. Mathematical models can help understand such a complex problem by providing a way to explore and conceptualize principles, merging biological knowledge with experimental data into a model amenable to simulation and external validation, all without the need for extensive clinical trials. We performed a scoping review of mathematical models describing the onset and evolution of Alzheimer's disease as a result of biophysical factors following the PRISMA standard. Our search strategy applied to the PubMed database yielded 846 entries. After using our exclusion criteria, only 17 studies remained from which we extracted data, which focused on three aspects of mathematical modeling: how authors addressed continuous time (since even when the measurements are punctual, the biological processes underlying Alzheimer's disease evolve continuously), howmodels were solved, and how the high dimensionality and non-linearity of models were managed. Most articles modeled Alzheimer's disease at the cellular level, operating on a short time scale (e.g., minutes or hours), i.e., the micro view (12/17); the rest considered regional or brain-level processes with longer timescales (e.g., years or decades) (the macro view). Most papers were concerned primarily with amyloid beta (n = 8), few described both amyloid beta and tau proteins (n = 3), while some considered more than these two factors (n = 6). Models used partial differential equations (n = 3), ordinary differential equations (n = 7), and both partial differential equations and ordinary differential equations (n = 3). Some did not specify their mathematical formalism (n = 4). Sensitivity analyses were performed in only a small number of papers (4/17). Overall, we found that only two studies could be considered valid in terms of parameters and conclusions, and two more were partially valid. This puts the majority (n = 13) as being either invalid or with insufficient information to ascertain their status. This was themain finding of our paper, in that serious shortcomings make their results invalid or non-reproducible. These shortcomings come from insufficient methodological description, poor calibration, or the impossibility of experimentally validating or calibrating the model. Those shortcomings should be addressed by future authors to unlock the usefulness of mathematicalmodels in Alzheimer's disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. New Insights in Prebiotic Utilization: A Systematic Review.
- Author
-
Arapović, Martina, Puljić, Leona, Kajić, Nikolina, Kartalović, Brankica, Habschied, Kristina, and Mastanjević, Krešimir
- Subjects
PREBIOTICS ,GUT microbiome ,FUNCTIONAL foods ,FOOD production ,PROBIOTICS ,DISEASE progression - Abstract
The hectic pace of modern life often leads to quick solutions, both in lifestyle and the choice of food we consume. The importance of the gut microbiome and its balance is being increasingly researched, with the prebiotic concept itself becoming a topic of scientific investigation. The aim of this paper is to analyze scientific studies on the understanding of prebiotics conducted between 2019 and 2024 in order to see what new knowledge, new sources, new ways of use, and newly established effects on certain disease states have been discovered during this period. The question that the authors are trying to answer is how specific prebiotics affect the growth and activity of selected probiotic strains in the human gut (have impact on gut microbiome) and what the implications of these interactions are. Four databases were searched: Pubmed/MEDLINE, Springerlink, Google Scholar, and Scopus. The keywords used were prebiotics, functional food, probiotics, gut microbiome, and trends. A systematic review of 30 scientific studies on the topic of prebiotics revealed significant advances in understanding and application. Research particularly indicates how prebiotics stimulate the growth of beneficial probiotic strains, such as Lacticaseibacillus rhamnosus, Lactiplantibacillus plantarum, and Bifidobacterium. In addition, innovative approaches in food production, including pasta rich in prebiotic fibers, chocolate with inulin and stevia, and the use of fruit by-products, show promising results in creating "healthier" food options. Although the papers had differing objectives and research methodologies, certain similarities were found. All papers emphasized the importance of using prebiotics, although it depended on the type they come from and their impact on the gut microbiome, i.e., the stimulation of probiotic action within the gut microbiome, which consequently has benefits on health. This review serves as a springboard for further research in this exciting field, with the ultimate goal of harnessing the power of prebiotics to improve health outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Neurophotonics: a comprehensive review, current challenges and future trends.
- Author
-
Barros, Beatriz Jacinto and Cunha, João P. S.
- Subjects
TECHNOLOGICAL innovations ,NEURAL circuitry ,SYSTEMS design ,DISEASE progression ,DATA management ,OPTOGENETICS ,BRAIN-computer interfaces - Abstract
The human brain, with its vast network of billions of neurons and trillions of synapses (connections) between diverse cell types, remains one of the greatest mysteries in science and medicine. Despite extensive research, an understanding of the underlying mechanisms that drive normal behaviors and response to disease states is still limited. Advancement in the Neuroscience field and development of therapeutics for related pathologies requires innovative technologies that can provide a dynamic and systematic understanding of the interactions between neurons and neural circuits. In this work, we provide an up-to-date overview of the evolution of neurophotonic approaches in the last 10 years through a multi-source, literature analysis. From an initial corpus of 243 papers retrieved from Scopus, PubMed and WoS databases, we have followed the PRISMA approach to select 56 papers in the area. Following a full-text evaluation of these 56 scientific articles, six main areas of applied research were identified and discussed: (1) Advanced optogenetics, (2) Multimodal neural interfaces, (3) Innovative therapeutics, (4) Imaging devices and probes, (5) Remote operations, and (6) Microfluidic platforms. For each area, the main technologies selected are discussed according to the photonic principles applied, the neuroscience application evaluated and the more indicative results of efficiency and scientific potential. This detailed analysis is followed by an outlook of the main challenges tackled over the last 10 years in the Neurophotonics field, as well as the main technological advances regarding specificity, light delivery, multimodality, imaging, materials and system designs. We conclude with a discussion of considerable challenges for future innovation and translation in Neurophotonics, from light delivery within the brain to physical constraints and data management strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. PPP1R14A as a potential biomarker for predicting the progression and prognosis of bladder cancer.
- Author
-
Lou K, Chi J, Zheng X, and Cui Y
- Subjects
- Humans, Prognosis, Male, Female, Urinary Bladder Neoplasms genetics, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms diagnosis, Biomarkers, Tumor blood, Disease Progression
- Abstract
Competing Interests: Declaration of competing interest All authors declare no conflict of interests in this paper.
- Published
- 2024
- Full Text
- View/download PDF
14. Tracking COPD exacerbation patterns and forecasting readmission risks utilizing electronic medical records.
- Author
-
Li J, Liang L, Samuel Cai Y, Zuo Y, Su J, Feng L, Wang H, and Tong Z
- Subjects
- Humans, Male, Female, Aged, Retrospective Studies, Middle Aged, Aged, 80 and over, Forecasting, Risk Assessment methods, Hospitalization statistics & numerical data, Risk Factors, Pulmonary Disease, Chronic Obstructive epidemiology, Patient Readmission statistics & numerical data, Electronic Health Records statistics & numerical data, Disease Progression
- Abstract
Introduction: Accurate evaluation of exacerbation frequency is an essential part of COPD assessment. But relying on just the prior-year exacerbation history may not capture the full picture of risk given the inherent year-to-year fluctuations in exacerbation rates. This study aimed to evaluate the predictive performance of models incorporating the 3-year exacerbation history based on electronic medical record., Materials and Methods: This retrospective cohort study included 86,501 COPD hospitalized patients in Beijing from 2008 to 2014. The annual frequency of COPD exacerbation hospitalizations over a 3-year period after the index hospitalization was calculated, with patients segmented into seven distinct exacerbation trajectory groups. Logistic regression was used to evaluate the predictive capability of the 3-year exacerbation history for exacerbation readmission in the fourth year. Predictors included age, sex, comorbidities, and exacerbation hospitalization in previous 1-3 years. Model performance was evaluated using area under the receiver operating characteristic curve (AUC)., Results: Of the studied patients, 56.5% were men, and the mean age (SD) was 73.8 (10.3) years. The overall readmission rate for COPD exacerbation was 0.31 per person-year, with only 3.8% of patients persistently readmitted over three consecutive years. The 3-year trajectory of exacerbation frequency was associated with exacerbation risk in the fourth year. Compared to just the prior year, the inclusion of a 3-year exacerbation hospitalization history notably improved prediction accuracy, with AUC elevating from 0.731 (0.724-0.739) to 0.786 (0.779-0.792)., Conclusion: These results unveil the fluctuating nature of COPD exacerbation hospitalization frequency across years and demonstrate that integrating a more comprehensive 3-year exacerbation history significantly refines the prediction model for future risk, thus providing a more nuanced and actionable insight for clinical care., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
15. CCL17 and CCL19 are markers of disease progression in alveolar echinococcosis.
- Author
-
Chen J, Ma Y, Liu Y, Zhao H, Qi X, Sun Y, Zhou X, Zhou J, Ma X, and Wang L
- Subjects
- Animals, Humans, Mice, Echinococcosis metabolism, Liver Cirrhosis parasitology, Liver Cirrhosis metabolism, Liver Cirrhosis pathology, Disease Models, Animal, Liver parasitology, Liver metabolism, Liver pathology, Echinococcosis, Hepatic metabolism, Echinococcosis, Hepatic parasitology, Female, Male, Hepatocytes metabolism, Hepatocytes parasitology, Disease Progression, Biomarkers metabolism, Chemokine CCL19 metabolism, Chemokine CCL17 metabolism, Chemokine CCL17 genetics
- Abstract
Objectives: Alveolar echinococcosis (AE) represents one of the deadliest helminthic infections, characterized by an insidious onset and high lethality., Methods: This study utilized the Gene Expression Omnibus (GEO) database, applied Weighted Correlation Network Analysis (WGCNA) and Differential Expression Analysis (DEA), and employed the Matthews Correlation Coefficient (MCC) to identify CCL17 and CCL19 as key genes in AE. Immunohistochemistry and immunofluorescence co-localization techniques were used to examine the expression of CCL17 and CCL19 in liver tissue lesions of AE patients. Additionally, a mouse model of multilocular echinococcus larvae infection was developed to study the temporal expression patterns of these genes, along with liver fibrosis and inflammatory responses., Results: The in vitro model simulating echinococcal larva infection mirrored the hepatic microenvironment post-infection with multilocular echinococcal tapeworms. Quantitative RT-PCR analysis showed that liver fibrosis occurred in AE patients, with proximal activation and increased expression of CCL17 and CCL19 over time post-infection. Notably, expression peaked during the late stages of infection. Similarly, F4/80, a macrophage marker, exhibited corresponding trends in expression. Upon stimulation of normal hepatocytes by vesicular larvae in cellular experiments, there was a significant increase in CCL17 and CCL19 expression at 12 h post-infection, mirroring the upregulation observed with F4/80., Conclusion: CCL17 and CCL19 facilitate macrophage aggregation via the chemokine pathway and their increased expression correlates with the progression of infection, suggesting their potential as biomarkers for AE progression., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
16. Functional elucidation of the EIF4A3-circR-4225-miR-507-TNFSF11 regulatory axis in LUAD and its role in tumor progression.
- Author
-
Wang G, Zhang Z, Wang J, Kang L, Zheng G, Liu B, Yang J, Sun Y, Zeng H, and Zhang Z
- Subjects
- Humans, Cell Line, Tumor, Apoptosis genetics, Female, Male, DEAD-box RNA Helicases, MicroRNAs genetics, MicroRNAs metabolism, Gene Expression Regulation, Neoplastic, RNA, Circular genetics, RNA, Circular metabolism, Cell Proliferation genetics, Disease Progression, Lung Neoplasms genetics, Lung Neoplasms pathology, Lung Neoplasms metabolism, Eukaryotic Initiation Factor-4A metabolism, Eukaryotic Initiation Factor-4A genetics, Adenocarcinoma of Lung genetics, Adenocarcinoma of Lung pathology, Adenocarcinoma of Lung metabolism
- Abstract
Lung adenocarcinoma (LUAD) is the most common subtypes of NSCLC. However, the therapeutic effects for LUAD are unsatisfactory at current stage, so it is important to find new molecular targets and therapeutic strategies. circRNAs can regulate the expression of target genes by binding to microRNAs (miRNAs) to form competitive endogenous RNAs (ceRNAs). Therefore, we investigated the functions of circR-4225 in the tumor progression of LUAD and its molecular mechanism in this paper. circR-4225 is up-regulated in LUAD tissues. EIF4A3, a member of the eukaryotic translation initiation factor 4A (EIF4A) family, promotes the expression of circR-4225. circR-4225 acts as a molecular sponge to down-regulate miR-507, which promotes the up-regulation of the expression of its target gene-tumor necrosis factor superfamily member 11 (TNFSF11). Knockdown of circR-4225 in the LUAD cell lines can inhibit cell proliferation and viability, and promote apoptosis of the LUAD cell lines, which can be reverted by inhibiting miR-507 or overexpressing TNFSF11. To sum it up, this study demonstrated that circR-4225 was significantly up-regulated in LUAD tissues, and circR-4225 promoted LUAD progression by sponging miR-507 and up-regulating TNFSF11. This study can provide new molecular targets for early diagnosis and treatment of LUAD., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
17. The use of artificial neural networks in studying the progression of glaucoma.
- Author
-
Târcoveanu F, Leon F, Lisa C, Curteanu S, Feraru A, Ali K, and Anton N
- Subjects
- Humans, Deep Learning, Glaucoma physiopathology, Glaucoma pathology, Neural Networks, Computer, Disease Progression
- Abstract
In ophthalmology, artificial intelligence methods show great promise due to their potential to enhance clinical observations with predictive capabilities and support physicians in diagnosing and treating patients. This paper focuses on modelling glaucoma evolution because it requires early diagnosis, individualized treatment, and lifelong monitoring. Glaucoma is a chronic, progressive, irreversible, multifactorial optic neuropathy that primarily affects elderly individuals. It is important to emphasize that the processed data are taken from medical records, unlike other studies in the literature that rely on image acquisition and processing. Although more challenging to handle, this approach has the advantage of including a wide range of parameters in large numbers, which can highlight their potential influence. Artificial neural networks are used to study glaucoma progression, designed through successive trials for near-optimal configurations using the NeuroSolutions and PyTorch frameworks. Furthermore, different problems are formulated to demonstrate the influence of various structural and functional parameters on the study of glaucoma progression. Optimal neural networks were obtained using a program written in Python using the PyTorch deep learning framework. For various tasks, very small errors in training and validation, under 5%, were obtained. It has been demonstrated that very good results can be achieved, making them credible and useful for medical practice., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
18. Definitions of pulmonary exacerbation in people with cystic fibrosis: a scoping review.
- Author
-
Almulhem M, Ward C, Haq I, Gray RD, and Brodlie M
- Subjects
- Humans, Cystic Fibrosis physiopathology, Cystic Fibrosis complications, Disease Progression
- Abstract
Background: Pulmonary exacerbations (PExs) are clinically important in people with cystic fibrosis (CF). Multiple definitions have been used for PEx, and this scoping review aimed to identify the different definitions reported in the literature and to ascertain which signs and symptoms are commonly used to define them., Methods: A search was performed using Embase, MEDLINE, Cochrane Library, Scopus and CINAHL. All publications reporting clinical trials or prospective observational studies involving definitions of PEx in people with CF published in English from January 1990 to December 2022 were included. Data were then extracted for qualitative thematic analysis., Results: A total of 14 039 records were identified, with 7647 titles and abstracts screened once duplicates were removed, 898 reviewed as full text and 377 meeting the inclusion criteria. Pre-existing definitions were used in 148 publications. In 75% of papers, an objective definition was used, while 25% used a subjective definition, which subcategorised into treatment-based definitions (76%) and those involving clinician judgement (24%). Objective definitions were subcategorised into three groups: those based on a combination of signs and symptoms (50%), those based on a predefined combination of signs and symptoms plus the initiation of acute treatment (47%) and scores involving different clinical features each with a specific weighting (3%). The most common signs and symptoms reported in the definitions were, in order, sputum production, cough, lung function, weight/appetite, dyspnoea, chest X-ray changes, chest sounds, fever, fatigue or lethargy and haemoptysis., Conclusion: We have identified substantial variation in the definitions of PEx in people with CF reported in the literature. There is a requirement for the development of internationally agreed-upon, standardised and validated age-specific definitions. Such definitions would allow comparison between studies and effective meta-analysis to be performed and are especially important in the highly effective modulator therapy era in CF care., Competing Interests: Competing interests: MB: Not related to this study, has been CI on investigator-led research grants from Pfizer and Roche Diagnostics; speaker fees paid to Newcastle University from Novartis, Roche Diagnostics, TEVA and Vertex Pharmaceuticals; travel expenses to educational meetings from Boehringer Ingelheim and Vertex Pharmaceuticals., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
19. T-cell acute lymphoblastic leukemia progression is supported by inflammatory molecules including hepatocyte growth factor.
- Author
-
Le Maout C, Fahy L, Renou L, Devanand C, Duwat C, Barroca V, Le Gall M, Ballerini P, Petit A, Calvo J, Uzan B, Pflumio F, and Petit V
- Subjects
- Animals, Mice, Mice, Inbred C57BL, Cell Line, Tumor, Inflammation pathology, Inflammation drug therapy, Inflammation metabolism, Inflammation Mediators metabolism, Neutrophils metabolism, Neutrophils drug effects, Monocytes drug effects, Monocytes metabolism, Monocytes pathology, Hepatocyte Growth Factor metabolism, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma pathology, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma metabolism, Disease Progression, Tumor Microenvironment
- Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is a malignant hematological disorder characterized by an increased proliferation of immature T lymphocytes precursors. T-ALL treatment includes chemotherapy with strong side effects, and patients that undergo relapse display poor prognosis. Although cell-intrinsic oncogenic pathways are well-studied, the tumor microenvironment, like inflammatory cellular and molecular components is less explored in T-ALL. We sought to determine the composition of the inflammatory microenvironment induced by T-ALL, and its role in T-ALL progression. We show in two mouse T-ALL cell models that T-ALLs enhance blood neutrophils and resident monocytes, accompanied with a plasmatic acute secretion of inflammatory molecules. Depleting neutrophils using anti-Ly6G treatment or resident monocytes by clodronate liposomes treatment does not modulate plasmatic inflammatory molecule secretion and mice survival. However, inhibiting the secretion of inflammatory molecules by microenvironment with NECA, an agonist of adenosine receptors, diminishes T-ALL progression enhancing mouse survival. We uncovered Hepatocyte Growth Factor (HGF), T-ALL-driven and the most decreased molecule with NECA, as a potential therapeutic target in T-ALL. Altogether, we identified a signature of inflammatory molecules that can potentially be involved in T-ALL evolution and uncovered HGF/cMET pathway as important to target for limiting T-ALL progression., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
20. Quercetin inhibits chronic stress-mediated progression of triple-negative breast cancer by blocking β 2 -AR/ERK1/2 pathway.
- Author
-
Zhang J, Teng F, Wu T, Li S, and Li K
- Subjects
- Animals, Female, Humans, Mice, Cell Line, Tumor, Cell Movement drug effects, Epinephrine pharmacology, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Lung Neoplasms metabolism, Mice, Inbred BALB C, Mice, Nude, Stress, Psychological drug therapy, Xenograft Model Antitumor Assays, Cell Proliferation drug effects, Disease Progression, MAP Kinase Signaling System drug effects, Quercetin pharmacology, Receptors, Adrenergic, beta-2 metabolism, Triple Negative Breast Neoplasms pathology, Triple Negative Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms metabolism
- Abstract
Chronic stress-mediated sustained release of neurotransmitters, which ultimately leads to the activation of β
2 -adrenergic receptor (β2 -AR) signaling, is one of the most important reasons for triple-negative breast cancer (TBNC) progression. Quercetin (Que) has been proven to have the advantage of ameliorating stress psychological disorder. Our present study aimed to investigate the effect of Que on tumor growth and metastasis in TNBC xenograft mice undergoing stress, and to explore its underlying mechanisms. We first evaluated the effect of Que on the progression of TNBC in nude mice in vivo. The results showed that, Que could inhibit chronic stress-induced TNBC growth and occurrence of lung metastasis. We subsequently employed epinephrine (E) as a representative of stress hormone to investigate its possible mechanism in vitro. The results showed that, Que could inhibit E-mediated proliferation and migration of TNBC cells by blocking β2 -AR/ERK1/2 pathway. In conclusion, our data demonstrated that Que could inhibit chronic stress-induced ERK1/2 activity in TNBC cells, and thereby weakening the potential for TNBC growth and metastasis., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
21. Imaging and Liquid Biopsy for Distinguishing True Progression From Pseudoprogression in Gliomas, Current Advances and Challenges.
- Author
-
Li K, Zhu Q, Yang J, Zheng Y, Du S, Song M, Peng Q, Yang R, Liu Y, and Qi L
- Subjects
- Humans, Liquid Biopsy methods, Diagnosis, Differential, Biomarkers, Tumor, Magnetic Resonance Imaging methods, Diffusion Magnetic Resonance Imaging methods, Glioma diagnostic imaging, Glioma pathology, Disease Progression, Brain Neoplasms diagnostic imaging, Brain Neoplasms pathology
- Abstract
Rationale and Objectives: Gliomas are aggressive brain tumors with a poor prognosis. Assessing treatment response is challenging because magnetic resonance imaging (MRI) may not distinguish true progression (TP) from pseudoprogression (PsP). This review aims to discuss imaging techniques and liquid biopsies used to distinguish TP from PsP., Materials and Methods: This review synthesizes existing literature to examine advances in imaging techniques, such as magnetic resonance diffusion imaging (MRDI), perfusion-weighted imaging (PWI) MRI, and liquid biopsies, for identifying TP or PsP through tumor markers and tissue characteristics., Results: Advanced imaging techniques, including MRDI and PWI MRI, have proven effective in delineating tumor tissue properties, offering valuable insights into glioma behavior. Similarly, liquid biopsy has emerged as a potent tool for identifying tumor-derived markers in biofluids, offering a non-invasive glimpse into tumor evolution. Despite their promise, these methodologies grapple with significant challenges. Their sensitivity remains inconsistent, complicating the accurate differentiation between TP and PSP. Furthermore, the absence of standardized protocols across platforms impedes the reliability of comparisons, while inherent biological variability adds complexity to data interpretation., Conclusion: Their potential applications have been highlighted, but gaps remain before routine clinical use. Further research is needed to develop and validate these promising methods for distinguishing TP from PsP in gliomas., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Yawei Liu provided a wealth of professional guidance for the revision of this manuscript. Runwei Yang provided linguistic advice for reworking the manuscript. Ling Qi reports financial support and article publishing charges were provided by Guangdong Basic and Applied Basic Research Foundation. LingQi reports financial support and article publishing charges were provided by Qingyuan Science and Technology Project. Kaishu Li reports financial support and article publishing charges were provided by the Medical Scientific Research Foundation of Guangdong Province. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
22. Analysing disease trajectories in a cohort of 71,849 Patients: A visual analytics and statistical approach.
- Author
-
Kerexeta-Sarriegi J, García-Navarro T, Rollan-Martinez-Herrera M, Larburu N, Espejo-Mambié MD, Beristain Iraola A, and Graña M
- Subjects
- Humans, Cohort Studies, Female, Male, Aged, Spain epidemiology, Middle Aged, Aged, 80 and over, Disease Progression
- Abstract
Background: Disease trajectories have become increasingly relevant within the context of an aging population and the rising prevalence of chronic illnesses. Understanding the temporal progression of diseases is crucial for enhancing patient care, preventive measures, and effective management., Objective: The objective of this study is to propose and validate a novel methodology for trajectory impact analysis and interactive visualization of disease trajectories over a cohort of 71,849 patients., Methods: This article introduces an innovative comprehensive approach for analysis and interactive visualization of disease trajectories. First, Risk Increase (RI) index is defined that assesses the impact of the initial disease diagnosis on the development of subsequent illnesses. Secondly, visual graphics methods are used to represent cohort trajectories, ensuring a clear and semantically rich presentation that facilitates easy data interpretation., Results: The proposed approach is demonstrated over the disease trajectories of a cohort comprising 71,849 patients from Tolosaldea, Spain. The study finds several clinically relevant trajectories in this cohort, such as that after suffering a cerebral ischemic stroke, the probability of suffering dementia increases 10.77 times. The clinical relevance of the study outcomes have been assessed by an in-depth analysis conducted by expert clinicians. The identified disease trajectories are in agreement with the latest advancements in the field., Conclusion: The proposed approach for trajectory impact analysis and interactive visualization offers valuable graphs for the comprehensive study of disease trajectories for improved clinical decision-making. The simplicity and interpretability of our methods make them valuable approach for healthcare professionals., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
23. IL-17A-induced cancer-associated fibroblasts releases CXCL12 to promote lung adenocarcinoma progression via Wnt/β-Catenin signaling pathway.
- Author
-
Lu X, Xu X, Zhou M, Ge J, Chen L, Yu W, and Wang H
- Subjects
- Humans, Animals, Mice, Male, Cell Line, Tumor, Cell Proliferation, Gene Expression Regulation, Neoplastic, beta Catenin metabolism, Interleukin-17 metabolism, Chemokine CXCL12 metabolism, Wnt Signaling Pathway, Cancer-Associated Fibroblasts metabolism, Cancer-Associated Fibroblasts pathology, Lung Neoplasms metabolism, Lung Neoplasms pathology, Adenocarcinoma of Lung metabolism, Adenocarcinoma of Lung pathology, Mice, Nude, Disease Progression, Mice, Inbred BALB C
- Abstract
Background: Cancer-associated fibroblasts (CAFs) and their secretion, C-X-C motif chemokine ligand 12 (CXCL12), play an important role in the development of lung adenocarcinoma (LUAD). Interleukin 17A (IL-17A) is also crucial in regulating tumor progression. Herein, we explored the specific relationships between these two factors and their mechanisms in the progression of LUAD., Methods: Immunohistochemistry was utilized to assess the differential expression levels of IL-17A and CXCL12 in tumor versus normal tissues of LUAD patients, followed by gene correlation analysis. Cell counting kit-8 (CCK8), wound-healing and transwell assays were performed to investigate the effect of IL-17A on the function of LUAD cells. qPCR, immunofluorescence, immunohistochemistry and western blot analyses were conducted to elucidate the potential mechanism by which IL-17A facilitates the development of LUAD via CXCL12. Male BALB-C nude mice were used to explore the role of IL-17A in subcutaneous LUAD mouse models., Results: Elevated expression levels of IL-17A and CXCL12 were observed in LUAD tissues, exhibiting a positive correlation. Further studies revealed that IL-17A could stimulate CAFs to enhance the release of CXCL12, thereby facilitating the growth, proliferation, and metastasis of LUAD. The binding of CXCL12 to its specific receptor influences the activation of the Wnt/β-Catenin pathway, which in turn affects the progression of LUAD. In vivo experiments have demonstrated that IL-17A enhances the growth of LUAD tumors by facilitating the secretion of CXCL12. Conversely, inhibiting CXCL12 has been demonstrated to impede tumor growth., Conclusions: We discovered that IL-17A promotes the release of CAFs-derived CXCL12, which in turn facilitates the development of LUAD via the Wnt/β-Catenin signaling pathway., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
24. Bridging Imaging and Clinical Scores in Parkinson's Progression via Multimodal Self-Supervised Deep Learning.
- Author
-
Martinez-Murcia FJ, Arco JE, Jimenez-Mesa C, Segovia F, Illan IA, Ramirez J, and Gorriz JM
- Subjects
- Humans, Supervised Machine Learning, Multimodal Imaging, Male, Female, Parkinson Disease diagnostic imaging, Parkinson Disease physiopathology, Deep Learning, Disease Progression, Neuroimaging methods
- Abstract
Neurodegenerative diseases pose a formidable challenge to medical research, demanding a nuanced understanding of their progressive nature. In this regard, latent generative models can effectively be used in a data-driven modeling of different dimensions of neurodegeneration, framed within the context of the manifold hypothesis. This paper proposes a joint framework for a multi-modal, common latent generative model to address the need for a more comprehensive understanding of the neurodegenerative landscape in the context of Parkinson's disease (PD). The proposed architecture uses coupled variational autoencoders (VAEs) to joint model a common latent space to both neuroimaging and clinical data from the Parkinson's Progression Markers Initiative (PPMI). Alternative loss functions, different normalization procedures, and the interpretability and explainability of latent generative models are addressed, leading to a model that was able to predict clinical symptomatology in the test set, as measured by the unified Parkinson's disease rating scale (UPDRS), with R2 up to 0.86 for same-modality and 0.441 cross-modality (using solely neuroimaging). The findings provide a foundation for further advancements in the field of clinical research and practice, with potential applications in decision-making processes for PD. The study also highlights the limitations and capabilities of the proposed model, emphasizing its direct interpretability and potential impact on understanding and interpreting neuroimaging patterns associated with PD symptomatology.
- Published
- 2024
- Full Text
- View/download PDF
25. Piezo1 activation accelerates osteoarthritis progression and the targeted therapy effect of artemisinin.
- Author
-
Gan D, Tao C, Jin X, Wu X, Yan Q, Zhong Y, Jia Q, Wu L, Huo S, Qin L, and Xiao G
- Subjects
- Animals, Humans, Mice, Cartilage, Articular metabolism, Cartilage, Articular drug effects, Male, Disease Models, Animal, Mice, Inbred C57BL, Pyrazines, Thiadiazoles, Artemisinins pharmacology, Ion Channels metabolism, Chondrocytes metabolism, Chondrocytes drug effects, Osteoarthritis drug therapy, Osteoarthritis metabolism, Disease Progression
- Abstract
Introduction: Osteoarthritis (OA) is a devastating whole-joint disease affecting a large population worldwide with no cure; its mechanism remains poorly defined. Abnormal mechanical stress is the main pathological factor of OA., Objectives: To investigate the effects of Piezo1 activation on OA development and progression and to explore Piezo1-targeting OA treatment., Methods: The expression levels of Piezo1 were determined in human OA cartilage and experimental OA mice. Mice with genetic Piezo1 deletion in chondrocytes or intra-articular injection of the Piezo1 activator Yoda1 were utilized to determine the effects on DMM-induced OA progression. Effects of artemisinin (ART), a potent antimalarial drug, on Piezo1 activation, chondrocyte metabolism and OA lesions were determined., Results: Piezo1 expression was elevated in articular chondrocytes in human OA and DMM-induced mouse OA cartilage. Piezo1 deletion in chondrocytes largely attenuates DMM-induced OA-like phenotypes. In contrast, intra-articular injection of Yoda1 aggravates the knee joint OA lesions in mice. PIEZO1 activation increases, while PIEZO1 siRNA knockdown decreases, expression of RUNX2 and catabolic enzymes MMP13 and ADAMTS5 in primary human articular chondrocytes in a PI3K-AKT dependent manner. We have provided strong evidence supporting that ART is a novel and potent inhibitor of Piezo1 activation in primary OA-HACs and all cell lines examined, including human endothelial HUVEC cells, ATDC5 chondrocyte-like cells and MLO-Y4 osteocytes-like cells. Results from in vitro experiments confirmed that ART decreases the Yoda1-induced increases in the levels of OA-related genes and p-PI3K and p-AKT proteins in OA-HACs and alleviates DMM-induced OA lesions in mice., Conclusions: We establish a critical role of Piezo1 in promoting OA development and progression and define ART as a potential OA treatment., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Production and hosting by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
26. [Clinical case of generalized amyloidosis (ATTR-amyloidosis) with a progressive course of chronic heart failure. Case report].
- Author
-
Golubovskaya DP, Dren' EV, Yurkina AV, Pecherina TB, and Barbarash OL
- Subjects
- Humans, Male, Fatal Outcome, Echocardiography methods, Amyloid Neuropathies, Familial diagnosis, Amyloid Neuropathies, Familial complications, Amyloid Neuropathies, Familial physiopathology, Middle Aged, Cardiomyopathies diagnosis, Cardiomyopathies etiology, Cardiomyopathies physiopathology, Heart Failure etiology, Heart Failure diagnosis, Disease Progression
- Abstract
Despite the presence of various signs of cardiac amyloidosis ("red flags"), the introduction into routine practice of new non-invasive diagnostic methods (Speckle Tracking technology using echocardiography, myocardial scintigraphy with technetium pyrophosphate, genetic testing, screening for free light chains of immunoglobulins to exclude AL-amyloidosis), which have high specificity and sensitivity, transthyretinic (ATTR) cardiomyopathy is still a difficult to diagnose disease, especially in the early stages when treatment is most effective. The article presents a clinical case of ATTR-amyloidosis with predominant heart damage, manifested by severe diastolic heart failure resistant to treatment. The timing, from the moment of the first episode of decompensation of heart failure to death, is 4 months, which confirms the rapid progression of severe biventricular dysfunction of the heart. Despite the presence of cardiac and extracardial "red flags" of ATTR-amyloidosis in the patient, the diagnosis was established at autopsy. The paper analyzes possible errors of early diagnosis at the outpatient and inpatient stages of patient management.
- Published
- 2024
- Full Text
- View/download PDF
27. Predicting return of lung function after a pulmonary exacerbation using the cystic fibrosis respiratory symptom diary-chronic respiratory infection symptom scale.
- Author
-
Gill ER, Goss CH, Sagel SD, Wright ML, Horner SD, and Zuñiga JA
- Subjects
- Humans, Female, Male, Longitudinal Studies, Adult, Young Adult, Adolescent, Lung physiopathology, Severity of Illness Index, Respiratory Tract Infections physiopathology, Respiratory Tract Infections diagnosis, Quality of Life, Linear Models, Forced Expiratory Volume, Respiratory Function Tests, Recovery of Function, Cystic Fibrosis physiopathology, Cystic Fibrosis complications, Disease Progression
- Abstract
Background: Pulmonary exacerbations (PExs) in people with cystic fibrosis (PwCF) are associated with increased healthcare costs, decreased quality of life and the risk for permanent decline in lung function. Symptom burden, the continuous physiological and emotional symptoms on an individual related to their disease, may be a useful tool for monitoring PwCF during a PEx, and identifying individuals at high risk for permanent decline in lung function. The purpose of this study was to investigate if the degree of symptom burden severity, measured by the Cystic Fibrosis Respiratory Symptom Diary (CFRSD)- Chronic Respiratory Infection Symptom Scale (CRISS), at the onset of a PEx can predict failure to return to baseline lung function by the end of treatment., Methods: A secondary analysis of a longitudinal, observational study (N = 56) was conducted. Data was collected at four time points: year-prior-to-enrollment annual appointment, termed "baseline", day 1 of PEx diagnosis, termed "Visit 1", day 10-21 of PEx diagnosis, termed "Visit 2" and two-weeks post-hospitalization, termed "Visit 3". A linear regression model was performed to analyze the research question., Results: A regression model predicted that recovery of lung function decreased by 0.2 points for every increase in CRISS points, indicating that participants with a CRISS score greater than 48.3 were at 14% greater risk of not recovering to baseline lung function by Visit 2, than people with lower scores., Conclusion: Monitoring CRISS scores in PwCF is an efficient, reliable, non-invasive way to determine a person's status at the beginning of a PEx. The results presented in this paper support the usefulness of studying symptoms in the context of PEx in PwCF., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
28. Glioma Stem Cells as Promoter of Glioma Progression: A Systematic Review of Molecular Pathways and Targeted Therapies.
- Author
-
Agosti E, Antonietti S, Ius T, Fontanella MM, Zeppieri M, and Panciani PP
- Subjects
- Humans, Molecular Targeted Therapy, Brain Neoplasms genetics, Brain Neoplasms pathology, Brain Neoplasms therapy, Brain Neoplasms metabolism, Animals, Signal Transduction, Neoplastic Stem Cells metabolism, Neoplastic Stem Cells pathology, Glioma genetics, Glioma pathology, Glioma therapy, Glioma metabolism, Disease Progression
- Abstract
Gliomas' aggressive nature and resistance to therapy make them a major problem in oncology. Gliomas continue to have dismal prognoses despite significant advancements in medical science, and traditional treatments like surgery, radiation (RT), and chemotherapy (CT) frequently prove to be ineffective. After glioma stem cells (GSCs) were discovered, the traditional view of gliomas as homogeneous masses changed. GSCs are essential for tumor growth, treatment resistance, and recurrence. These cells' distinct capacities for differentiation and self-renewal are changing our knowledge of the biology of gliomas. This systematic literature review aims to uncover the molecular mechanisms driving glioma progression associated with GSCs. The systematic review adhered to PRISMA guidelines, with a thorough literature search conducted on PubMed, Ovid MED-LINE, and Ovid EMBASE. The first literature search was performed on 1 March 2024, and the search was updated on 15 May 2024. Employing MeSH terms and Boolean operators, the search focused on molecular mechanisms associated with GCSs-mediated glioma progression. Inclusion criteria encompassed English language studies, preclinical studies, and clinical trials. A number of 957 papers were initially identified, of which 65 studies spanning from 2005 to 2024 were finally included in the review. The main GSC model distribution is arranged in decreasing order of frequency: U87: 20 studies (32.0%); U251: 13 studies (20.0%); A172: 4 studies (6.2%); and T98G: 2 studies (3.17%). From most to least frequent, the distribution of the primary GSC pathway is as follows: Notch: 8 studies (12.3%); STAT3: 6 studies (9.2%); Wnt/β-catenin: 6 studies (9.2%); HIF: 5 studies (7.7%); and PI3K/AKT: 4 studies (6.2%). The distribution of molecular effects, from most to least common, is as follows: inhibition of differentiation: 22 studies (33.8%); increased proliferation: 18 studies (27.7%); enhanced invasive ability: 15 studies (23.1%); increased self-renewal: 5 studies (7.7%); and inhibition of apoptosis: 3 studies (4.6%). This work highlights GSC heterogeneity and the dynamic interplay within the glioblastoma microenvironment, underscoring the need for a tailored approach. A few key pathways influencing GSC behavior are JAK/STAT3, PI3K/AKT, Wnt/β-catenin, and Notch. Therapy may target these pathways. This research urges more study to fill in knowledge gaps in the biology of GSCs and translate findings into useful treatment approaches that could improve GBM patient outcomes.
- Published
- 2024
- Full Text
- View/download PDF
29. DNA demethylase TET2-mediated reduction of HADHB expression contributes to cadmium-induced malignant progression of colorectal cancer.
- Author
-
Li L, Jiang M, Wang W, Cao X, Ma Q, Han J, Liu Z, Huang Y, and Chen Y
- Subjects
- Humans, Animals, Mice, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins metabolism, Cell Line, Tumor, Male, Cell Proliferation drug effects, Female, Mice, Nude, DNA Methylation drug effects, Cell Movement drug effects, Colorectal Neoplasms pathology, Colorectal Neoplasms genetics, Colorectal Neoplasms chemically induced, Dioxygenases genetics, Cadmium toxicity, DNA-Binding Proteins genetics, DNA-Binding Proteins metabolism, Disease Progression
- Abstract
Environmental exposure to the cadmium (Cd) has been shown to be a risk factor for colorectal cancer (CRC) progression, but the exact mechanism has not been fully elucidated. In this study, we found that chronic Cd (3 μM) exposure promoted the proliferation, adhesion, migration, and invasion of CRC cells in vitro, as well as lung metastasis in vivo. RNA-seq and TCGA-COAD datasets revealed that decreased hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta (HADHB) expression may be a crucial factor in Cd-induced CRC progression. Further analysis using qRT-PCR and tissue microarrays from CRC patients showed that HADHB expression was significantly reduced in CRC tissues compared to adjacent normal tissues, and low HADHB expression was associated with adverse clinical features and poor overall survival, either directly or through TNM stage. Furthermore, HADHB was found to play an important role in the Cd-induced malignant metastatic phenotype of CRC cells and lung metastasis in mice. Mechanistically, we discovered that chronic Cd exposure resulted in hypermethylation of the HADHB promoter region via inhibition of DNA demethylase tet methylcytosine dioxygenase 2 (TET2), which then led to decreased HADHB expression and activation of the FAK signaling pathway, and ultimately contributed to CRC progression. In conclusion, this study provided a new potential insight and evaluable biomarker for Cd exposure-induced CRC progression and treatment., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
30. Temporal stratification of amyotrophic lateral sclerosis patients using disease progression patterns.
- Author
-
M Amaral D, Soares DF, Gromicho M, de Carvalho M, Madeira SC, Tomás P, and Aidos H
- Subjects
- Humans, Male, Cluster Analysis, Female, Middle Aged, Aged, Amyotrophic Lateral Sclerosis pathology, Amyotrophic Lateral Sclerosis physiopathology, Disease Progression
- Abstract
Identifying groups of patients with similar disease progression patterns is key to understand disease heterogeneity, guide clinical decisions and improve patient care. In this paper, we propose a data-driven temporal stratification approach, ClusTric, combining triclustering and hierarchical clustering. The proposed approach enables the discovery of complex disease progression patterns not found by univariate temporal analyses. As a case study, we use Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative disease with a non-linear and heterogeneous disease progression. In this context, we applied ClusTric to stratify a hospital-based population (Lisbon ALS Clinic dataset) and validate it in a clinical trial population. The results unravelled four clinically relevant disease progression groups: slow progressors, moderate bulbar and spinal progressors, and fast progressors. We compared ClusTric with a state-of-the-art method, showing its effectiveness in capturing the heterogeneity of ALS disease progression in a lower number of clinically relevant progression groups., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
31. Recent advances in hematopoietic cell kinase in cancer progression: Mechanisms and inhibitors.
- Author
-
Zeng Q, He J, Chen X, Yuan Q, Yin L, Liang Y, Zu X, and Shen Y
- Subjects
- Humans, Animals, Antineoplastic Agents therapeutic use, Antineoplastic Agents pharmacology, Signal Transduction drug effects, Tumor Microenvironment, Molecular Targeted Therapy, Neoplasms drug therapy, Neoplasms enzymology, Neoplasms pathology, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors pharmacology, Disease Progression, Proto-Oncogene Proteins c-hck metabolism, Proto-Oncogene Proteins c-hck antagonists & inhibitors
- Abstract
Hematopoietic cell kinase (Hck), a non-receptor tyrosine kinase belonging to the Src kinase family, is intricately linked to the pathogenesis of numerous human diseases, with a particularly pronounced association with cancer. Hck not only directly impacts the proliferation, migration, and apoptosis of cancer cells but also interacts with JAK/STAT, MEK/ERK, PI3K/AKT, CXCL12/CXCR4, and other pathways. Hck also influences the tumor microenvironment to facilitate the onset and progression of cancer. This paper delves into the functional role and regulatory mechanisms of Hck in various solid tumors. Additionally, it explores the implications of Hck in hematological malignancies. The review culminates with a summary of the current research status of Hck inhibitors, the majority of which are in the pre-clinical phase of investigation. Notably, these inhibitors are predominantly utilized in the therapeutic management of leukemia, with their combinatorial potential indicating promising avenues for future research. In conclusion, this review underscores the significance of the mechanism of Hck in solid tumors. This insight is crucial for comprehending the current research trends regarding Hck: targeted therapy against Hck shows great promise in both diagnosis and treatment of malignant tumors. Further investigation into the role of Hck in cancer, coupled with the development of specific inhibitors, has the potential to revolutionize approaches to cancer treatment., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Masson SAS.)
- Published
- 2024
- Full Text
- View/download PDF
32. The efficacy and safety of soluble guanylate cyclase modulation in patients with heart failure: a comprehensive meta-analysis of randomized controlled trials.
- Author
-
Arayici, Mehmet Emin, Gunes, Hakan, Ellidokuz, Hulya, and Yilmaz, Mehmet Birhan
- Subjects
GUANYLATE cyclase ,HEART failure patients ,RANDOMIZED controlled trials ,DISEASE progression ,MORTALITY - Abstract
Soluble guanylate cyclase (sGC) modulation has been scrutinized in several disease states including heart failure (HF). Recently, it was shown that an sGC modulator improved HF-related hospitalization significantly, though, there was no benefit related to mortality. Herein, a comprehensive meta-analysis of randomized controlled trials (RCTs) for sGC modulation in HF patients was provided in agreement with the PRISMA statement. A total of 10 RCTs yielding 12 papers were included. There were 7526 patients with heart failure of each phenotype, 4253 in the sGC modulator group and 3273 in the placebo group. Use of sGC modulators in HF patients yielded no significant difference in the risk of all-cause mortality compared to placebo (RR = 0.97, 95% CI 0.88–1.08, p = 0.62). The use of sGC modulators was associated with a trend toward a considerable but non-significant increase in the incidence of SAEs (RR = 1.10, 95% CI 0.99–1.22, p = 0.07), as well as an increased incidence of hypotension and anemia. There was an overall neutral effect of sGC modulation on NT-proBNP levels, 6MWD and mortality, at a cost of slight increase in hypotension and anemia. Of note, the improvement in EQ-5D-based quality of life was significant. Hence, the benefit seems to be driven by distinctive domains of quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Serum Interleukins 8, 17, and 33 as Potential Biomarkers of Colon Cancer.
- Author
-
Tâlvan, Constantin-Dan, Budișan, Liviuța, Tâlvan, Elena-Teodora, Grecu, Valentin, Zănoagă, Oana, Mihalache, Cosmin, Cristea, Victor, Berindan-Neagoe, Ioana, and Mohor, Călin Ilie
- Subjects
INTERLEUKINS ,COLON tumors ,DISEASE progression ,CYTOKINES ,METASTASIS ,EARLY detection of cancer ,TUMOR classification ,COMPARATIVE studies ,TUMOR markers - Abstract
Simple Summary: This research studied how three types of proteins, called interleukins (namely 8, 17A and 33), are present in the blood of healthy people and people with colon cancer. Colon cancer is a disease that affects the large intestine. The paper looked at 82 people, 42 of whom had colon cancer and 40 of whom did not. The researchers divided the cancer patients into four groups based on how severe their cancer was. The study measured the amount of interleukins in the blood of each person using a special test. The paper analyzed the results of the test, considering the age, gender, and cancer stage of each person. The results showed that younger people, and those with less severe cancer had more interleukins in their blood. The paper also found that two of the interleukins (8 and 17A) were higher in the cancer group, while one of them (33) was higher in the healthy group. The study also found that the interleukins were related to each other in both groups. This research concluded that the interleukins might help detect colon cancer and predict how it will progress. This paper could help improve the diagnosis and treatment of colon cancer. This research investigated the serum levels of three interleukins (IL8, IL17A, and IL33) and the possible relationships between them in healthy people and colon cancer patients at different stages. This study involved 82 participants, 42 of whom had colon cancer and 40 were healthy individuals. The cancer patients were classified into four groups according to the TNM staging classification of colon and rectal cancer. Serum levels of the interleukins were measured by the ELISA test. The data were analyzed statistically to compare the demographic characteristics, the interleukin levels across cancer stages, and the correlation between interleukins in both groups. The results showed that women had more early-stage colon cancer diagnoses, while men had more advanced-stage cancer diagnoses. Stage two colon cancer was more common in older people. Younger people, men, and those with early-stage colon cancer had higher levels of interleukins. The levels of IL8 and IL17A were higher in the cancer group, while the level of IL33 was higher in the healthy group. There was a strong correlation between IL8 and IL17A levels in both groups (p = 0.001). IL17A influenced the level of IL33 in the cancer group (p = 0.007). This study suggested that cytokine variation profiles could be useful for detecting colon cancer and predicting its outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Assessing the Influence of Climate Change and Environmental Factors on the Top Tick-Borne Diseases in the United States: A Systematic Review.
- Author
-
Deshpande, Gargi, Beetch, Jessica E., Heller, John G., Naqvi, Ozair H., and Kuhn, Katrin Gaardbo
- Subjects
TICK-borne diseases ,LYME disease ,CLIMATE change ,VECTOR-borne diseases ,DISEASE progression - Abstract
In the United States (US), tick-borne diseases (TBDs) have more than doubled in the past fifteen years and are a major contributor to the overall burden of vector-borne diseases. The most common TBDs in the US—Lyme disease, rickettsioses (including Rocky Mountain spotted fever), and anaplasmosis—have gradually shifted in recent years, resulting in increased morbidity and mortality. In this systematic review, we examined climate change and other environmental factors that have influenced the epidemiology of these TBDs in the US while highlighting the opportunities for a One Health approach to mitigating their impact. We searched Medline Plus, PUBMED, and Google Scholar for studies focused on these three TBDs in the US from January 2018 to August 2023. Data selection and extraction were completed using Covidence, and the risk of bias was assessed with the ROBINS-I tool. The review included 84 papers covering multiple states across the US. We found that climate, seasonality and temporality, and land use are important environmental factors that impact the epidemiology and patterns of TBDs. The emerging trends, influenced by environmental factors, emphasize the need for region-specific research to aid in the prediction and prevention of TBDs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Prognostic marker VPS72 could promote the malignant progression of prostate cancer.
- Author
-
Xu X, Wang W, He Y, Yao Y, and Yang B
- Subjects
- Aged, Humans, Male, Middle Aged, Androgen Antagonists therapeutic use, Androgen Antagonists pharmacology, Cell Line, Tumor, Cell Movement genetics, Gene Expression Regulation, Neoplastic, Nomograms, Prognosis, Vesicular Transport Proteins genetics, Vesicular Transport Proteins metabolism, Biomarkers, Tumor metabolism, Biomarkers, Tumor genetics, Cell Proliferation, Disease Progression, Prostatic Neoplasms pathology, Prostatic Neoplasms genetics, Prostatic Neoplasms metabolism
- Abstract
Background: This paper attempted to clarify the role and mechanism of vacuolar protein sorting-associated protein 72 homolog (VPS72) in the progression of prostate cancer (PCa)., Methods: Clinical information and gene expression profiles of patients with prostate cancer were obtained from The Cancer Genome Atlas (TCGA). VPS72 expression in PCa and the potential mechanism by which VPS72 affects PCa progression was investigated. Next, we performed COX regression analysis to identify the independent prognostic factors of PCa, and constructed a nomogram. The sensitivity of chemotherapeutic medications was anticipated using "pRRophetic". Subsequently, in vitro assays to validate the effect of VPS72 on PCa cell proliferation, migration and susceptibility to anti-androgen therapy., Results: The expression of VPS72 was considerably higher in PCa tissues compared to normal tissues. Significant correlations were found between high VPS72 expression and a poor prognosis and adverse clinicopathological factors. The nomogram model constructed based on VPS72 expression has good predictive performance. According to GSEA, VPS72-related genes were enriched in the NF-kB pathways, cytokine-cytokine receptor interaction and chemokine signaling pathway in PCa. Although PCa with low VPS72 expression was more adaptable to chemotherapeutic medications, our in vitro experiment showed that VPS72 knockdown significantly decreased the PCa cell migration, proliferation, and resistance to anti-androgen therapy., Conclusions: In summary our findings suggests that VPS72 could play a crucial role in the malignant progression of PCa, and its expression level can be employed as a possible biomarker of PCa prognosis., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
36. The biological roles of CD47 in ovarian cancer progression.
- Author
-
Xing L, Wang Z, Feng Y, Luo H, Dai G, Sang L, Zhang C, and Qian J
- Subjects
- Humans, Female, Immunotherapy methods, Animals, CD47 Antigen metabolism, CD47 Antigen immunology, Ovarian Neoplasms immunology, Ovarian Neoplasms metabolism, Ovarian Neoplasms pathology, Disease Progression
- Abstract
Ovarian cancer is one of the most lethal malignant tumors, characterized by high incidence and poor prognosis. Patients relapse occurred in 65-80% after initial treatment. To date, no effective treatment has been established for these patients. Recently, CD47 has been considered as a promising immunotherapy target. In this paper, we reviewed the biological roles of CD47 in ovarian cancer and summarized the related mechanisms. For most types of cancers, the CD47/Sirpα immune checkpoint has attracted the most attention in immunotherapy. Notably, CD47 monoclonal antibodies and related molecules are promising in the immunotherapy of ovarian cancer, and further research is needed. In the future, new immunotherapy regimens targeting CD47 can be applied to the clinical treatment of ovarian cancer patients., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
37. GLUT3 transcriptional activation by ZEB1 fuels the Warburg effect and promotes ovarian cancer progression.
- Author
-
Lin F, Ma L, Yu S, Lin J, Xu Z, Xia H, Song Y, Huang W, Wu Y, Chen Y, Liu X, Xia J, and Huang X
- Subjects
- Humans, Female, Cell Line, Tumor, Glycolysis genetics, Animals, Cell Proliferation genetics, Mice, Promoter Regions, Genetic, Mice, Nude, Zinc Finger E-box-Binding Homeobox 1 genetics, Zinc Finger E-box-Binding Homeobox 1 metabolism, Glucose Transporter Type 3 genetics, Glucose Transporter Type 3 metabolism, Ovarian Neoplasms genetics, Ovarian Neoplasms pathology, Ovarian Neoplasms metabolism, Gene Expression Regulation, Neoplastic, Transcriptional Activation, Disease Progression, Warburg Effect, Oncologic
- Abstract
Ovarian cancer (OvCa) is characterized by early metastasis and high mortality rates, underscoring the need for deeper understanding of these aspects. This study explores the role of glucose transporter 3 (GLUT3) driven by zinc finger E-box-binding homeobox 1 (ZEB1) in OvCa progression and metastasis. Specifically, this study explored whether ZEB1 promotes glycolysis and assessed the potential involvement of GLUT3 in this process in OvCa cells. Our findings revealed that ZEB1 and GLUT3 were excessively expressed and closely correlated in OvCa. Mechanistically, ZEB1 activates the transcription of GLUT3 by binding to its promoter region. Increased expression of GLUT3 driven by ZEB1 dramatically enhances glycolysis, and thus fuels Warburg Effect to promote OvCa progression and metastasis. Consistently, elevated ZEB1 and GLUT3 expression in clinical OvCa is correlated with poor prognosis, reinforcing the profound contribution of ZEB1-GLUT3 axis to OvCa. These results suggest that activation of GLUT3 expression by ZEB1 is crucial for the proliferation and metastasis of OvCa via fueling glycolysis, shedding new light on OvCa treatment., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
38. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
- Author
-
Noureddin N, Copur-Dahi N, and Loomba R
- Subjects
- Humans, Non-alcoholic Fatty Liver Disease complications, Non-alcoholic Fatty Liver Disease metabolism, Biomarkers metabolism, Fatty Liver, Metabolic Syndrome complications, Disease Progression
- Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease. Its prevalence is increasing with the epidemic of obesity and metabolic syndrome. MASLD progression into metabolic dysfunction-associated steatohepatitis (MASH) and advanced fibrosis may lead to decompensated cirrhosis and development of liver-related events, hepatocellular carcinoma and death. Monitoring disease progression is critical in decreasing morbidity, mortality, need for transplant and economic burden. Assessing for treatment response once FDA-approved medications are available is still an unmet clinical need., Aims: To explore the most up-to-date literature on testing used for monitoring disease progression and treatment response METHODS: We searched PubMed from inception to 15 August 2023, using the following MeSH terms: 'MASLD', 'Metabolic dysfunction-associated steatotic liver disease', 'MASH', 'metabolic dysfunction-associated steatohepatitis', 'Non-Alcoholic Fatty Liver Disease', 'NAFLD', 'non-alcoholic steatohepatitis', 'NASH', 'Biomarkers', 'clinical trial'. Articles were also identified through searches of the authors' files. The final reference list was generated based on originality and relevance to this review's broad scope, considering only papers published in English., Results: We have cited 101 references in this review detailing methods to monitor MASLD disease progression and treatment response., Conclusion: Various biomarkers can be used in different care settings to monitor disease progression. Further research is needed to validate noninvasive tests more effectively., (© 2023 John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
39. BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury.
- Author
-
Saiz ML, Lozano-Chamizo L, Florez AB, Marciello M, Diaz-Bulnes P, Corte-Iglesias V, Bernet CR, Rodrigues-Diez RR, Martin-Martin C, Rodriguez-Santamaria M, Fernandez-Vega I, Rodriguez RM, Diaz-Corte C, Suarez-Alvarez B, Filice M, and Lopez-Larrea C
- Subjects
- Animals, Mice, Male, Transcription Factors antagonists & inhibitors, Transcription Factors metabolism, Acute Kidney Injury drug therapy, Acute Kidney Injury prevention & control, Disease Models, Animal, Nanoparticles, Cell Cycle Proteins antagonists & inhibitors, Azepines pharmacology, Azepines administration & dosage, Reperfusion Injury drug therapy, Reperfusion Injury pathology, Triazoles pharmacology, Triazoles administration & dosage, Renal Insufficiency, Chronic drug therapy, Renal Insufficiency, Chronic pathology, Disease Progression, Mice, Inbred C57BL, Kidney drug effects, Kidney pathology, Kidney metabolism, Liposomes, Bromodomain Containing Proteins, Nuclear Proteins
- Abstract
Targeting epigenetic mechanisms has emerged as a potential therapeutic approach for the treatment of kidney diseases. Specifically, inhibiting the bromodomain and extra-terminal (BET) domain proteins using the small molecule inhibitor JQ1 has shown promise in preclinical models of acute kidney injury (AKI) and chronic kidney disease (CKD). However, its clinical translation faces challenges due to issues with poor pharmacokinetics and side effects. Here, we developed engineered liposomes loaded with JQ1 with the aim of enhancing kidney drug delivery and reducing the required minimum effective dose by leveraging cargo protection. These liposomes efficiently encapsulated JQ1 in both the membrane and core, demonstrating superior therapeutic efficacy compared to freely delivered JQ1 in a mouse model of kidney ischemia-reperfusion injury. JQ1-loaded liposomes (JQ1-NPs) effectively targeted the kidneys and only one administration, one-hour after injury, was enough to decrease the immune cell (neutrophils and monocytes) infiltration to the kidney-an early and pivotal step to prevent damage progression. By inhibiting BRD4, JQ1-NPs suppress the transcription of pro-inflammatory genes, such as cytokines (il-6) and chemokines (ccl2, ccl5). This success not only improved early the kidney function, as evidenced by decreased serum levels of BUN and creatinine in JQ1-NPs-treated mice, along with reduced tissue expression of the damage marker, NGAL, but also halted the production of extracellular matrix proteins (Fsp-1, Fn-1, α-SMA and Col1a1) and the fibrosis development. In summary, this work presents a promising nanotherapeutic strategy for AKI treatment and its progression and provides new insights into renal drug delivery., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Masson SAS.)
- Published
- 2024
- Full Text
- View/download PDF
40. Predicting disease-related MRI patterns of multiple sclerosis through GAN-based image editing.
- Author
-
Güllmar D, Hsu WC, and Reichenbach JR
- Subjects
- Humans, Adult, Male, Female, Brain diagnostic imaging, Deep Learning, Middle Aged, Image Processing, Computer-Assisted methods, Multiple Sclerosis diagnostic imaging, Magnetic Resonance Imaging methods, Disease Progression
- Abstract
Introduction: Multiple sclerosis (MS) is a complex neurodegenerative disorder that affects the brain and spinal cord. In this study, we applied a deep learning-based approach using the StyleGAN model to explore patterns related to MS and predict disease progression in magnetic resonance images (MRI)., Methods: We trained the StyleGAN model unsupervised using T
1 -weighted GRE MR images and diffusion-based ADC maps of MS patients and healthy controls. We then used the trained model to resample MR images from real input data and modified them by manipulations in the latent space to simulate MS progression. We analyzed the resulting simulation-related patterns mimicking disease progression by comparing the intensity profiles of the original and manipulated images and determined the brain parenchymal fraction (BPF)., Results: Our results show that MS progression can be simulated by manipulating MR images in the latent space, as evidenced by brain volume loss on both T1 -weighted and ADC maps and increasing lesion extent on ADC maps., Conclusion: Overall, this study demonstrates the potential of the StyleGAN model in medical imaging to study image markers and to shed more light on the relationship between brain atrophy and MS progression through corresponding manipulations in the latent space., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Author(s). Published by Elsevier GmbH.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
41. Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies.
- Author
-
Trnkova L, Buocikova V, Mego M, Cumova A, Burikova M, Bohac M, Miklikova S, Cihova M, and Smolkova B
- Subjects
- Humans, Female, Animals, DNA Methylation genetics, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm genetics, Tumor Microenvironment genetics, Epigenesis, Genetic, Breast Neoplasms genetics, Breast Neoplasms pathology, Breast Neoplasms drug therapy, Disease Progression
- Abstract
Breast cancer comprises a substantial proportion of cancer diagnoses in women and is a primary cause of cancer-related mortality. While hormone-responsive cases generally have a favorable prognosis, the aggressive nature of triple-negative breast cancer presents challenges, with intrinsic resistance to established treatments being a persistent issue. The complexity intensifies with the emergence of acquired resistance, further complicating the management of breast cancer. Epigenetic changes, encompassing DNA methylation, histone and RNA modifications, and non-coding RNAs, are acknowledged as crucial contributors to the heterogeneity of breast cancer. The unique epigenetic landscape harbored by each cellular component within the tumor microenvironment (TME) adds great diversity to the intricate regulations which influence therapeutic responses. The TME, a sophisticated ecosystem of cellular and non-cellular elements interacting with tumor cells, establishes an immunosuppressive microenvironment and fuels processes such as tumor growth, angiogenesis, and extracellular matrix remodeling. These factors contribute to challenging conditions in cancer treatment by fostering a hypoxic environment, inducing metabolic stress, and creating physical barriers to drug delivery. This article delves into the complex connections between breast cancer treatment response, underlying epigenetic changes, and vital interactions within the TME. To restore sensitivity to treatment, it emphasizes the need for combination therapies considering epigenetic changes specific to individual members of the TME. Recognizing the pivotal role of epigenetics in drug resistance and comprehending the specificities of breast TME is essential for devising more effective therapeutic strategies. The development of reliable biomarkers for patient stratification will facilitate tailored and precise treatment approaches., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
42. Unveiling Selected Influences on Chronic Kidney Disease Development and Progression.
- Author
-
Fularski P, Czarnik W, Frankenstein H, Gąsior M, Młynarska E, Rysz J, and Franczyk B
- Subjects
- Humans, Animals, Hypertension physiopathology, Hypertension pathology, Vascular Calcification metabolism, Vascular Calcification pathology, Vascular Calcification physiopathology, Transforming Growth Factor beta1 metabolism, Kidney pathology, Kidney metabolism, Kidney physiopathology, Renal Insufficiency, Chronic pathology, Renal Insufficiency, Chronic metabolism, Disease Progression, Renin-Angiotensin System physiology
- Abstract
Currently, more and more people are suffering from chronic kidney disease (CKD). It is estimated that CKD affects over 10% of the population worldwide. This is a significant issue, as the kidneys largely contribute to maintaining homeostasis by, among other things, regulating blood pressure, the pH of blood, and the water-electrolyte balance and by eliminating unnecessary metabolic waste products from blood. What is more, this disease does not show any specific symptoms at the beginning. The development of CKD is predisposed by certain conditions, such as diabetes mellitus or hypertension. However, these disorders are not the only factors promoting the onset and progression of CKD. The primary purpose of this review is to examine renin-angiotensin-aldosterone system (RAAS) activity, transforming growth factor-β1 (TGF-β1), vascular calcification (VC), uremic toxins, and hypertension in the context of their impact on the occurrence and the course of CKD. We firmly believe that a deeper comprehension of the cellular and molecular mechanisms underlying CKD can lead to an enhanced understanding of the disease. In the future, this may result in the development of medications targeting specific mechanisms involved in the decline of kidney function. Our paper unveils the selected processes responsible for the deterioration of renal filtration abilities.
- Published
- 2024
- Full Text
- View/download PDF
43. Modifiable risk factors that may be addressed in routine care to prevent progression to and extension of multimorbidity in people with COPD: a systematic literature review.
- Author
-
Orlowski A, Ettinger J, Bottle A, Snow S, Ashton R, and Quint JK
- Subjects
- Humans, Quality of Life, Risk Factors, Disease Progression, Multimorbidity, Pulmonary Disease, Chronic Obstructive epidemiology, Pulmonary Disease, Chronic Obstructive therapy
- Abstract
Chronic obstructive pulmonary disease (COPD) is a multisystem disease, and many patients have multiple conditions. We explored multimorbidity patterns that might inform intervention planning to reduce health-care costs while preserving quality of life for patients. Literature searches up to February 2022 revealed 4419 clinical observational and comparative studies of risk factors for multimorbidity in people with COPD, pulmonary emphysema, or chronic bronchitis at baseline. Of these, 29 met the inclusion criteria for this review. Eight studies were cluster and network analyses, five were regression analyses, and 17 (in 16 papers) were other studies of specific conditions, physical activity and treatment. People with COPD more frequently had multimorbidity and had up to ten times the number of disorders of those without COPD. Disease combinations prominently featured cardiovascular and metabolic diseases, asthma, musculoskeletal and psychiatric disorders. An important risk factor for multimorbidity was low socioeconomic status. One study showed that many patients were receiving multiple drugs and had increased risk of adverse events, and that 10% of medications prescribed were inappropriate. Many patients with COPD have mainly preventable or modifiable multimorbidity. A proactive multidisciplinary approach to prevention and management could reduce the burden of care., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
44. The role and mechanism of TXNDC5 in disease progression.
- Author
-
Jiao M, Zhang Y, Song X, and Xu B
- Subjects
- Humans, Fibrosis, Neoplasms genetics, Disease Progression, Protein Disulfide-Isomerases genetics, Protein Disulfide-Isomerases metabolism
- Abstract
Thioredoxin domain containing protein-5 (TXNDC5), also known as endothelial protein-disulfide isomerase (Endo-PDI), is confined to the endoplasmic reticulum through the structural endoplasmic reticulum retention signal (KDEL), is a member of the PDI protein family and is highly expressed in the hypoxic state. TXNDC5 can regulate the rate of disulfide bond formation, isomerization and degradation of target proteins through its function as a protein disulfide isomerase (PDI), thereby altering protein conformation, activity and improving protein stability. Several studies have shown that there is a significant correlation between TXNDC5 gene polymorphisms and genetic susceptibility to inflammatory diseases such as rheumatoid, fibrosis and tumors. In this paper, we detail the expression characteristics of TXNDC5 in a variety of diseases, summarize the mechanisms by which TXNDC5 promotes malignant disease progression, and summarize potential therapeutic strategies to target TXNDC5 for disease treatment., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Jiao, Zhang, Song and Xu.)
- Published
- 2024
- Full Text
- View/download PDF
45. Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models.
- Author
-
Milani M, Della Valle I, Rossi S, Fabbrizio P, Margotta C, Nardo G, Cozzolino M, D'Ambrosi N, and Apolloni S
- Subjects
- Animals, Mice, Disease Models, Animal, Inflammation drug therapy, Mice, Transgenic, RNA-Binding Protein FUS genetics, RNA-Binding Protein FUS metabolism, Superoxide Dismutase-1 genetics, Superoxide Dismutase-1 metabolism, Amyotrophic Lateral Sclerosis drug therapy, Amyotrophic Lateral Sclerosis genetics, Amyotrophic Lateral Sclerosis pathology, Disease Progression, Neuroprotective Agents pharmacology, Neuroprotective Agents therapeutic use, Niclosamide pharmacology, Niclosamide therapeutic use
- Abstract
Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease influenced by genetic, epigenetic, and environmental factors, resulting in dysfunction in cellular and molecular pathways. The limited efficacy of current treatments highlights the need for combination therapies targeting multiple aspects of the disease. Niclosamide, an anthelminthic drug listed as an essential medicine, has been repurposed in clinical trials for different diseases due to its anti-inflammatory and anti-fibrotic properties. Niclosamide can inhibit various molecular pathways (e.g., STAT3, mTOR) that are dysregulated in ALS, suggesting its potential to disrupt these altered mechanisms associated with the pathology. We administered niclosamide intraperitoneally to two transgenic murine models, SOD1-G93A and FUS mice, mimicking key pathological processes of ALS. The treatment was initiated at the onset of symptoms, and we assessed disease progression by neurological scores, rotarod and wire tests, and monitored survival. Furthermore, we investigated cellular and molecular mechanisms affected by niclosamide in the spinal cord and muscle of ALS mice. In both models, the administration of niclosamide resulted in a slowdown of disease progression, an increase in survival rates, and an improvement in tissue pathology. This was characterised by reduced gliosis, motor neuron loss, muscle atrophy, and inflammatory pathways. Based on these results, our findings demonstrate that niclosamide can impact multiple pathways involved in ALS. This multi-targeted approach leads to a slowdown in the progression of the disease, positioning niclosamide as a promising candidate for repurposing in the treatment of ALS., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
46. Mechanisms of chondrocyte cell death in osteoarthritis: implications for disease progression and treatment.
- Author
-
Guan, Mengqi, Yu, Qingyuan, Zhou, Guohui, Wang, Yan, Yu, Jianan, Yang, Wei, and Li, Zhenhua
- Subjects
OSTEOARTHRITIS treatment ,AUTOPHAGY ,RESEARCH funding ,DISEASE management ,APOPTOSIS ,MORPHOGENESIS ,CARTILAGE cells ,CELL death ,OSTEOARTHRITIS ,MOLECULAR biology ,DISEASE progression - Abstract
Osteoarthritis (OA) is a chronic joint disease characterized by the degeneration, destruction, and excessive ossification of articular cartilage. The prevalence of OA is rising annually, concomitant with the aging global population and increasing rates of obesity. This condition imposes a substantial and escalating burden on individual health, healthcare systems, and broader social and economic frameworks. The etiology of OA is multifaceted and not fully understood. Current research suggests that the death of chondrocytes, encompassing mechanisms such as cellular apoptosis, pyroptosis, autophagy, ferroptosis and cuproptosis, contributes to both the initiation and progression of the disease. These cell death pathways not only diminish the population of chondrocytes but also exacerbate joint damage through the induction of inflammation and other deleterious processes. This paper delineates the morphological characteristics associated with various modes of cell death and summarizes current research results on the molecular mechanisms of different cell death patterns in OA. The objective is to review the advancements in understanding chondrocyte cell death in OA, thereby offering novel insights for potential clinical interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Updates in Alzheimer's disease: from basic research to diagnosis and therapies.
- Author
-
Liu, Enjie, Zhang, Yao, and Wang, Jian-Zhi
- Subjects
ALZHEIMER'S disease ,NEUROFIBRILLARY tangles ,AMYLOID plaque ,NEURODEGENERATION ,DISEASE progression - Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized pathologically by extracellular deposition of β-amyloid (Aβ) into senile plaques and intracellular accumulation of hyperphosphorylated tau (pTau) as neurofibrillary tangles. Clinically, AD patients show memory deterioration with varying cognitive dysfunctions. The exact molecular mechanisms underlying AD are still not fully understood, and there are no efficient drugs to stop or reverse the disease progression. In this review, we first provide an update on how the risk factors, including APOE variants, infections and inflammation, contribute to AD; how Aβ and tau become abnormally accumulated and how this accumulation plays a role in AD neurodegeneration. Then we summarize the commonly used experimental models, diagnostic and prediction strategies, and advances in periphery biomarkers from high-risk populations for AD. Finally, we introduce current status of development of disease-modifying drugs, including the newly officially approved Aβ vaccines, as well as novel and promising strategies to target the abnormal pTau. Together, this paper was aimed to update AD research progress from fundamental mechanisms to the clinical diagnosis and therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. A future of AI-driven personalized care for people with multiple sclerosis.
- Author
-
Praet, Jelle, Anderhalten, Lina, Comi, Giancarlo, Horakova, Dana, Ziemssen, Tjalf, Vermersch, Patrick, Lukas, Carsten, van Leemput, Koen, Steppe, Marjan, Aguilera, Cristina, Kadas, Ella Maria, Bertrand, Alexis, van Rampelbergh, Jean, de Boer, Erik, Zingler, Vera, Smeets, Dirk, Ribbens, Annemie, and Paul, Friedemann
- Subjects
DIAGNOSIS ,QUALITY of life ,PROGNOSTIC models ,CENTRAL nervous system ,MULTIPLE sclerosis - Abstract
Multiple sclerosis (MS) is a devastating immune-mediated disorder of the central nervous system resulting in progressive disability accumulation. As there is no cure available yet for MS, the primary therapeutic objective is to reduce relapses and to slow down disability progression as early as possible during the disease to maintain and/or improve health-related quality of life. However, optimizing treatment for people with MS (pwMS) is complex and challenging due to the many factors involved and in particular, the high degree of clinical and subclinical heterogeneity in disease progression among pwMS. In this paper, we discuss these many different challenges complicating treatment optimization for pwMS as well as how a shift towards a more pro-active, data-driven and personalized medicine approach could potentially improve patient outcomes for pwMS. We describe how the ‘Clinical Impact through AI-assisted MS Care’ (CLAIMS) project serves as a recent example of how to realize such a shift towards personalized treatment optimization for pwMS through the development of a platform that offers a holistic view of all relevant patient data and biomarkers, and then using this data to enable AI-supported prognostic modelling. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Aneurysm growth evaluation and detection: a computer-assisted follow-up MRA analysis.
- Author
-
Bizjak, Žiga and Špiclin, Žiga
- Subjects
DISEASE progression ,INTRACRANIAL aneurysms ,ANGIOGRAPHY ,SURFACE area ,INFORMATION resources management - Abstract
Growing intracranial aneurysms pose a high risk of rupture, making the detection and quantification of the growth crucial for timely treatment strategy adoption. In this paper we propose a computer-assisted approach based on the extraction of IA shapes from associated baseline and follow-up angiographic scans and non-rigid morphing of the two shapes. From the obtained shape deformations we computed four novel features, including differential volume (dV), surface area (dSA), aneurysm-size normalized median deformation path length (dMPL), and integral of cumulative deformation distances (dICDD). An experienced neuroradiologist manually extracted the IA shape models from the baseline and follow-up MRAs and, by utilizing size change and visual assessments, classified each aneurysm into stable with morphology changes, stable or growing. We investigated the classification performance and found that three of the novel and one cross-sectional feature exhibited significantly different mean values (p-value < 0.05 ; Tukey's HSD test) between the stable and growing IA groups, while the mean dICDD was significantly different between all the three groups. The cross-sectional features has sensitivity to growing IAs in range 0.05–0.86, while novel features had generally higher sensitivity in range 0.81–0.90, making them promising candidates as surrogate follow-up imaging-based biomarkers for IA growth detection. These findings may offer valuable information for clinical management of patients with IAs based on follow-up imaging. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. The roles of AIM2 in neurodegenerative diseases: insights and therapeutic implications.
- Author
-
Kai Yang, Xi Wang, Hanyu Pan, Xinqing Wang, Yunhan Hu, Yihe Yao, Xinyue Zhao, and Taolei Sun
- Subjects
PARKINSON'S disease ,ALZHEIMER'S disease ,NEURODEGENERATION ,DISEASE progression ,CELLULAR signal transduction - Abstract
AIM2, a cytosolic innate immune receptor, has the capability to recognize doublestranded DNA (dsDNA). This paper delineates the structural features of AIM2 and its mechanisms of activation, emphasizing its capacity to detect cytosolic DNA and initiate inflammasome assembly. Additionally, we explore the diverse functions of AIM2 in different cells. Insights into AIM2-mediated neuroinflammation provide a foundation for investigating novel therapeutic strategies targeting AIM2 signaling pathways. Furthermore, we present a comprehensive review of the roles of AIM2 in neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD). Finally, we discuss its therapeutic implications. In conclusion, a profound understanding of AIM2 in neurodegenerative diseases may facilitate the development of effective interventions to mitigate neuronal damage and slow disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.